Zhi‐Ming Shao

Nanjing University of Chinese Medicine — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

45h-index12.9kcitations356works4.62yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(86), Cancer Genomics and Diagnostics(79), HER2/EGFR in Cancer Research(70), Cancer Immunotherapy and Biomarkers(57), Advanced Breast Cancer Therapies(54)

Publications356 total

Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities

UNC Libraries·2025Open Access

The top 100 most cited articles on pediatric respiratory syncytial virus pneumonia over the last 30 years: a bibliometric analysis

Tropical Medicine and Health·2025Open Access

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial

1 cited

The Lancet Oncology·2025· 1 cited

Supplementary Data from Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer

2025Open Access

Supplementary Data from Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer

2025Open Access

Landscape of gene fusions in hormone receptor-positive breast cancer reveals ADK fusions as drivers of progression and potential therapeutic targets

Cell Discovery·2025Open Access

Comprehensive investigation of the molecular basis of cancer dependencies suggests therapeutic options for breast cancer

Cancer Biology and Medicine·2025Open Access

Table S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

2025Open Access

Table S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

2025Open Access

Figure S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

2025Open Access

Table S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

2025Open Access

Table S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

2025Open Access

Data from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

2025Open Access

Figure S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

2025Open Access

Figure S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

2025Open Access

Figure S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

2025Open Access

Table S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

2025Open Access

Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

2025Open Access

Table S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

2025Open Access

Figure S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

2025Open Access

page 1 of 18Next →

Frequent Co-authors

Yi‐Zhou Jiang(12), Ke‐Da Yu(7), Yi Xiao(7), Jiong Wu(7), Da‐Qiang Li(6), Xi Jin(6), Eric P. Winer(5), Angelo Di Leo(5), Michael Gnant(5), Semiglazov Vf(5), Shen Zhao(5), Zhenzhou Shen(5), Martine Piccart(4), Beat Thürlimann(4), Fabrice André(4), Fátima Cardoso(4), Giuseppe Curigliano(4), Bent Ejlertsen(4), Jacek Jassem(4), Zefei Jiang(4)